Rothschild & Co. Asset Management US Inc. Raises Holdings in Orthofix Medical Inc (NASDAQ:OFIX)

Rothschild & Co. Asset Management US Inc. lifted its stake in Orthofix Medical Inc (NASDAQ:OFIX) by 2.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 236,502 shares of the medical device company’s stock after buying an additional 6,413 shares during the quarter. Rothschild & Co. Asset Management US Inc. owned approximately 1.24% of Orthofix Medical worth $12,506,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Mason Street Advisors LLC boosted its stake in shares of Orthofix Medical by 4.2% in the first quarter. Mason Street Advisors LLC now owns 6,122 shares of the medical device company’s stock worth $345,000 after buying an additional 246 shares during the last quarter. Laurion Capital Management LP purchased a new stake in shares of Orthofix Medical in the first quarter worth about $623,000. Municipal Employees Retirement System of Michigan purchased a new stake in shares of Orthofix Medical in the fourth quarter worth about $287,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of Orthofix Medical by 332.8% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 6,159 shares of the medical device company’s stock worth $323,000 after buying an additional 4,736 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its stake in shares of Orthofix Medical by 5.4% in the first quarter. Great West Life Assurance Co. Can now owns 25,347 shares of the medical device company’s stock worth $1,427,000 after buying an additional 1,300 shares during the last quarter. Hedge funds and other institutional investors own 94.30% of the company’s stock.

In other Orthofix Medical news, CEO Brad Mason sold 8,890 shares of the stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $51.11, for a total transaction of $454,367.90. Following the completion of the transaction, the chief executive officer now owns 159,053 shares of the company’s stock, valued at $8,129,198.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 5.80% of the company’s stock.

A number of brokerages have recently commented on OFIX. TheStreet downgraded Orthofix Medical from a “b+” rating to a “c+” rating in a research note on Thursday, May 9th. Zacks Investment Research cut Orthofix Medical from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 10th. ValuEngine cut Orthofix Medical from a “buy” rating to a “hold” rating in a report on Saturday, May 18th. Finally, BidaskClub raised Orthofix Medical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $60.00.

NASDAQ OFIX traded down $0.91 during trading hours on Wednesday, reaching $52.03. The company’s stock had a trading volume of 56,124 shares, compared to its average volume of 158,127. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of 26.55, a price-to-earnings-growth ratio of 2.98 and a beta of 0.42. Orthofix Medical Inc has a 1-year low of $47.79 and a 1-year high of $74.44. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.52 and a quick ratio of 2.28. The firm has a 50-day moving average price of $51.67.

Orthofix Medical (NASDAQ:OFIX) last released its quarterly earnings results on Monday, August 5th. The medical device company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.12). The business had revenue of $115.85 million during the quarter, compared to analyst estimates of $115.17 million. Orthofix Medical had a return on equity of 10.45% and a net margin of 2.09%. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.42 EPS. As a group, sell-side analysts expect that Orthofix Medical Inc will post 1.77 earnings per share for the current fiscal year.

Orthofix Medical Profile

Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and therapies worldwide. It operates through four segments: Bone Growth Therapies, Spinal Implants, Biologics, and Orthofix Extremities. The Bone Growth Therapies segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spinal appendicular fractures.

Featured Article: What does cost of debt say about a company’s financial health?

Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix Medical Inc (NASDAQ:OFIX).

Institutional Ownership by Quarter for Orthofix Medical (NASDAQ:OFIX)

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.